Search
Search Results
-
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer
BackgroundThis study aimed to elucidate the clinicopathological and molecular features of HER2 -amplified and HER2-low colorectal cancers (CRCs). We...
-
HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
BackgroundBreast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough...
-
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
PurposeOne-half of hormone receptor-positive (HR +) breast cancer (BC) patients have low expression of HER2 (HER2-low) and may benefit from...
-
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients...
-
Clinicopathological features and prognosis of patients with HER2-low breast cancer
BackgroundLow human epidermal growth factor receptor 2 (HER2) expression is an emerging concept in breast cancer that is defined as...
-
Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
BackgroundHER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We...
-
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment...
-
Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
BackgroundNovel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of the HER2-low subtype....
-
Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study
BackgroundNovel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug...
-
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
BackgroundPrevious studies have suggested that patients with HER2-low breast cancers do not benefit from trastuzumab treatment although the reasons...
-
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
BackgroundCurrent guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates...
-
High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
BackgroundConsidering the recent advancements in the treatment of breast cancer with low expression of human epidermal growth factor receptor 2...
-
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases
BackgroundHER2-low breast cancers (BC) show a good response to novel anti-HER2 antibody-drug conjugates (ADCs) in advanced setting. Nevertheless,...
-
Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis
The development of novel anti-HER2 drugs opens new treatment options for women with breast cancers, including lower expression of HER2. The...
-
Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
BackgroundHER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and...
-
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
BackgroundThe “HER2-low” nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 ...
-
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
BackgroundHER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC)...
-
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of...
-
Evolution of HER2-low expression from primary to recurrent breast cancer
About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this...
-
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression...
